AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

AIM ImmunoTech Inc. announced a $2.4 million financing consisting of a registered direct offering of 7.5 million shares at $0.325 per share and concurrent private placement of Series I Warrants to purchase 15 million shares. The company plans to use proceeds for manufacturing clinical drug supply, Phase 3 clinical trial activities, and working capital. The offering is expected to close on May 21, 2026.

05/20/2026, 3:02 PM • GlobeNewswire

AIM ImmunoTech Provides Routine Update on Annual Filings

AIM ImmunoTech Inc. disclosed that its 2025 audited financial statements contain a going concern emphasis of matter from its independent auditors. Despite this, management expressed confidence in its ability to raise funds based on positive progress in Phase 2 clinical trials of its lead drug Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer. The company expects to release the next DURIPANC study update in June 2026.

04/13/2026, 6:00 PM • GlobeNewswire

Why Is AIM ImmunoTech Stock Gaining Today?

AIM ImmunoTech stock surged 73.66% to $1.21 after securing full approval for a Japanese patent protecting the use of Ampligen combined with checkpoint inhibitors for cancer treatment, particularly pancreatic cancer. The patent extends through December 2039, strengthening the company's intellectual property position in a major global pharmaceutical market. AIM plans to pursue orphan drug designation in Japan and already holds similar designations in the U.S. and EU.

03/18/2026, 12:08 PM • Benzinga

AIM ImmunoTech Announces Closing of its Rights Offering

AIM ImmunoTech Inc. announced the closing of its rights offering, which raised approximately $1.8 million. The offering allowed investors to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants. The company is focused on developing Ampligen (rintatolimod) for treating late-stage pancreatic cancer.

03/06/2026, 7:00 PM • GlobeNewswire

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

AIM ImmunoTech announced the expiration of its rights offering on March 3, 2026, which generated approximately $1.8 million in gross proceeds. The offering allowed shareholders to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants at $1,000 per unit. The company expects the offering to close on or about March 6, 2026.

03/04/2026, 9:00 AM • Benzinga

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

AIM ImmunoTech Inc. announced a rights offering expected to raise $12 million in gross proceeds. Shareholders of record as of February 4, 2026 will receive one non-transferable subscription right per share to purchase units consisting of Series G Convertible Preferred Stock and warrants at $1,000 per unit. The subscription period runs from February 5-23, 2026. Net proceeds will fund clinical trials, manufacturing expenses for pancreatic cancer trials, and debt repayment.

01/23/2026, 1:22 PM • GlobeNewswire

AIM ImmunoTech Announces Stock Dividend

AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 outstanding shares of common stock, as well as one share for every outstanding option or warrant. The dividend is payable to shareholders of record on January 9, 2026, with distribution to DTCC on January 13, 2026. Fractional shares will be rounded down with cash compensation at $1.305 per share.

12/30/2025, 5:10 PM • Benzinga

AIM ImmunoTech Announces Stock Dividend

AIM ImmunoTech Inc. announced a stock dividend of one share per 1,000 outstanding shares, with a record date of January 9, 2026 and distribution date of January 13, 2026. Fractional shares will be paid in cash at $1.305 per share. The company is an immuno-pharma firm developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen (rintatolimod).

12/30/2025, 5:10 PM • GlobeNewswire

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.

12/16/2025, 1:17 PM • Benzinga

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech reported positive mid-year data for Ampligen in pancreatic cancer treatment, combining with AstraZeneca's Imfinzi, and raised $8 million in a public equity offering to fund operations for approximately 12 months.

08/15/2025, 9:00 AM • GlobeNewswire

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech will present clinical research on its drug Ampligen at the 5th Annual Marie Skłodowska-Curie Symposium, highlighting promising results in pancreatic cancer treatment and potential applications in endometriosis.

08/06/2025, 9:00 AM • GlobeNewswire